Technology
Health
Biotechnology
Myovant Sciences
$24.299876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$24.29
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$1.32 (5.75%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell MYOV and other stocks, options, ETFs, and crypto commission-free!
About
Myovant Sciences Ltd., also called Myovant Sciences, is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of women's health and endocrine diseases. Read More The company's product includes relugolix, which is an oral, once-daily and small molecule that acts as a GnRH receptor antagonist. It also develops MVT-602 a kisspeptin agonist for the treatment of female infertility. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.
CEO
Employees
86
Headquarters
London, Greater London
Founded
2016
Market Cap
1.63B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
79.95K
High Today
$24.47
Low Today
$22.90
Open Price
$22.90
Volume
722.19K
52 Week High
$27.45
52 Week Low
$14.32
Collections
Technology
Health
Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
2016 IPO
UK
News
MarketBeatMar 3
Stock Price, News, & Analysis for Myovant Sciences
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, fo...
Price Paid on Robinhood
40% Higher
Right Now
52 Week Low
$14.32
Average Price Paid
$17.34
52 Week High
$27.45
Earnings
-$1.04
-$0.79
-$0.55
-$0.30
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Estimated
—
Actual
Expected Jun 6, After Hours